Skip to content
ESPT
MARKETS / NASDAQ / Health care / Medical devices and instruments / ICUI
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · LARGE CAP

ICU Medical Inc. ICUI

19 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.2B
▼ 6.3% YoY
$732,000
$91.8M
▼ 26.4% YoY

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

ICU develops, manufactures, and sells medical products used in infusion therapy, vascular access, and vital care applications. At December 31, 2025, the company had approximately 13,000 employees located in over 35 countries. Its manufacturing facilities are concentrated in the United States, Costa Rica, Mexico, and Czech Republic. In 2025, 2024, and 2023, the company had worldwide net sales to a single distributor of 18%, 18%, and 16% of consolidated net sales, respectively. It offers a portfolio of infusion pumps, dedicated IV sets, software, and professional services to meet a range of infusion needs. Headquartered in San Clemente, California, ICU was founded in 1984.

Written from the business description in ICU MEDICAL INC/DE's annual report to the U.S. Securities and Exchange Commission, filed 19 February 2026. Every sentence was checked against that document before publication.

Growth

USD 2.2B
Revenue, FY2025 · full 19-year series below
Revenue $B Net income $B
FY2025 · Revenue 2.2 · Net income 0.0
1B2B
2007201020132016201920222025
Compound annual growth
−0.7%
+11.9%
+20.6%
+14.8%
−61.5%
−33.8%
−21.9%
−62.5%
−36.3%
−24.8%
+8.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +11.9% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

0 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 1.9% · Net 0.0%
10%20%-2%-4%
200720162025
ROE
FY2025 · ROE 0.0%
5%10%15%-2%-4%
200720162025
Three returns, three denominators.
Gross margin36.8%
Operating margin1.9%
Net margin0.0%
EBITDAUSD 243.6M

Each USD of equity produced 0 cents of profit this year.

Cash & shareholders

USD 2.7M
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF 91.8
100M200M-100M-200M
200720162025
Net buybacks $M Dividends $M
FY2025 · Dividends · · Net buybacks 2.7
15M30M-10M-20M
2007201020132016201920222025
Dividends paid·
Net buybacksUSD 2.7M
Share of profit363.4%
Consecutive raises·

USD 2.7M in buybacks — 363% of the year's profit, so the payout drew on cash built up earlier.

Total assetsUSD 4.1B
EquityUSD 2.1B
CashUSD 308.0M
Gross debtUSD 1.3B
Net debtUSD 976.7M
Current ratio2.39×

Net debt stands at 46% of equity.

The 19-year record

19 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative—not applicable◌not available in our data
ICUI, 19-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010200920082007
Revenue $B2.22.42.32.31.31.31.31.41.30.40.30.30.30.30.30.30.20.20.2
Operating income $B0.00.00.0−0.00.10.10.10.0−0.00.10.10.00.10.10.10.00.00.00.0
EBITDA $B0.20.30.30.20.20.20.20.10.10.10.10.10.10.10.10.10.10.00.0
Income tax $B0.00.1−0.0−0.00.00.00.0−0.0−0.00.00.00.00.00.00.00.00.00.00.0
Net income $B0.0−0.1−0.0−0.10.10.10.10.00.10.10.00.00.00.00.00.00.00.00.0
Free cash flow $B0.10.10.1−0.20.20.10.00.10.10.10.10.00.00.00.00.00.00.00.0
EPS, diluted $0.03−4.83−1.23−3.114.744.024.691.333.293.662.731.682.652.803.152.161.671.671.51
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend———————————————————
ROE %0.0−5.8−1.4−4.06.66.07.72.37.410.28.35.49.411.615.111.29.710.410.8
Shares out B0.020.020.020.020.020.020.020.020.020.020.020.020.020.010.010.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

MCK · COR · CAH · JNJ · HCA · LLY
Provenance

Company facts, as filed

How we verify · 0 failures in 93 reconciliationsAUDITED

Reconciled in 19 of the 19 fiscal years we could check. Two checks were skipped: the balance sheet is not tagged before 2008.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
Data on record since2007

Share this section

Download image